Apixaban Raw Material Powder 99% White Powder CAS 503612-47-3 Raw Material Powder

Introduction to Apixaban (503612-47-3)

Apixaban, with the chemical formula C25H25N5O4 and CAS number 503612-47-3, is a novel oral anticoagulant belonging to the class of direct factor Xa inhibitors. Approved by regulatory agencies for medical use, apixaban has gained significant attention for its efficacy and safety profile in various thromboembolic conditions. This comprehensive description elucidates the pharmacological properties, therapeutic indications, mechanism of action, pharmacokinetics, adverse effects, and potential drug interactions associated with apixaban.

Pharmacological Properties

Apixaban exerts its pharmacological effects by specifically inhibiting factor Xa, a key enzyme involved in the coagulation cascade. Unlike traditional anticoagulants such as warfarin, apixaban acts directly on factor Xa, thereby disrupting the formation of thrombin and preventing the conversion of fibrinogen to fibrin. This mechanism offers a targeted approach to anticoagulation with potentially fewer adverse effects.

Therapeutic Indications

Apixaban is primarily indicated for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation. Additionally, it is used for the treatment and prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE) following initial therapy. The versatility of apixaban extends to the prophylaxis of venous thromboembolism (VTE) in patients undergoing elective hip or knee replacement surgery.

Mechanism of Action

The pharmacodynamic action of apixaban involves selective inhibition of both free and clot-bound factor Xa without requiring a cofactor (such as antithrombin III). By impeding the activity of factor Xa, apixaban disrupts the amplification of the coagulation cascade, thereby preventing the formation of thrombi.

Pharmacokinetics

Apixaban exhibits predictable pharmacokinetics with a bioavailability of approximately 50% following oral administration. Peak plasma concentrations are achieved within 3 to 4 hours post-dose. The drug undergoes metabolism primarily via cytochrome P450 enzymes, with the majority of the metabolites being excreted renally. The elimination half-life of apixaban is approximately 12 hours in healthy individuals, necessitating twice-daily dosing for therapeutic efficacy.

Adverse Effects

Common adverse effects associated with apixaban therapy include bleeding complications, such as gastrointestinal bleeding and intracranial hemorrhage. Patients may also experience adverse reactions such as anemia, nausea, and edema. Close monitoring of hemoglobin levels and renal function is recommended during apixaban therapy to mitigate the risk of adverse events.

Drug Interactions

Apixaban is metabolized by cytochrome P450 enzymes, particularly CYP3A4 and CYP3A5. Therefore, concomitant use of strong inhibitors or inducers of these enzymes may alter apixaban plasma concentrations, leading to potential therapeutic failure or increased risk of bleeding, respectively. Additionally, drugs that affect P-glycoprotein (P-gp) activity may influence apixaban pharmacokinetics. Healthcare providers should carefully evaluate potential drug interactions before initiating apixaban therapy.

Conclusion

In conclusion, apixaban represents a significant advancement in anticoagulant therapy due to its selective inhibition of factor Xa and favorable pharmacokinetic properties. With its proven efficacy in various thromboembolic conditions and relatively low risk of adverse effects compared to traditional anticoagulants, apixaban has become a cornerstone in the management of atrial fibrillation, venous thromboembolism, and thromboprophylaxis following orthopedic surgery. However, cautious monitoring and awareness of potential drug interactions are essential to ensure the safe and effective use of apixaban in clinical practice.